The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
Open accessAbstract
BACKGROUND: Apolipoprotein C-III (APOC3) is a key regulator of plasma triglyceride levels. Elevated triglyceride levels are associated with a risk of adverse cardiovascular events and pancreatitis. ISIS 304801 is a second-generation antisense inhibitor of APOC3 synthesis. METHODS: We conducted a randomized, double-blind, placebo-controlled, dose-ranging, phase 2 study to evaluate ISIS 304801 in untreated patients with fasting triglyceride levels between 350 mg per deciliter (4.0 mmol per liter) and 2000 mg per deciliter (22.6 mmol per liter) (ISIS 304801 monotherapy cohort), as well as in patients receiving stable fibrate therapy who had fasting triglyceride levels between 225 mg per deciliter (2.5 mmol per liter) and 2000 mg per deciliter (ISIS 304801-fibrate cohort). Eligible patients were randomly assigned to receive either ISIS 304801, at doses ranging from 100 to 300 mg, or placebo, once weekly for 13 weeks. The primary outcome was the percentage change in APOC3 level from baseline. RESULTS: A total of 57 patients were treated in the ISIS 304801 monotherapy cohort (41 received active agent, and 16 received placebo), and 28 patients were treated in the ISIS 304801-fibrate cohort (20 received active agent, and 8 received placebo). The mean (±SD) baseline triglyceride levels in the two cohorts were 581±291 mg per deciliter (6.6±3.3 mmol per liter) and 376±188 mg per deciliter (4.2±2.1 mmol per liter), respectively. Treatment with ISIS 304801 resulted in dose-dependent and prolonged decreases in plasma APOC3 levels when the drug was administered as a single agent (decreases of 40.0±32.0% in the 100-mg group, 63.8±22.3% in the 200-mg group, and 79.6±9.3% in the 300-mg group, vs. an increase of 4.2±41.7% in the placebo group) and when it was administered as an add-on to fibrates (decreases of 60.2±12.5% in the 200-mg group and 70.9±13.0% in the 300-mg group, vs. a decrease of 2.2±25.2% in the placebo group). Concordant reductions of 31.3 to 70.9% were observed in triglyceride levels. No safety concerns were identified in this short-term study. CONCLUSIONS: We found that treatment with ISIS 304801 was associated with significant lowering of triglyceride levels, among patients with a broad range of baseline levels, through selective antisense inhibition of APOC3 synthesis. (Funded by Isis Pharmaceuticals; ClinicalTrials.gov number, NCT01529424.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In a randomized, placebo-controlled, double-blind phase 2 trial of 57 patients with elevated triglycerides, volanesorsen reduced ApoC-III by up to − 80% and triglycerides by − 71% [175].”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [175]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Volanesorsen is an antisense oligonucleotide that targets APOC3 messenger RNA (mRNA) and reduces plasma apolipoprotein C-III levels, as well as the degree of chylomicronemia and plasma triglyceride levels.”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [24]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Volanesorsen (previously known as ISIS-APOC-III RX ) is a second-generation ASO developed to inhibit apoCIII”
From The Forgotten Lipids: Triglycerides, Remnant Cholesterol, and Atherosclerotic Cardiovascular Disease Risk (2019) · cites this paper as [170]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Volanesorsen, a second-generation antisense oligonucleotide (ASO) targeting hepatic APOC3 mRNA, has shown the capacity to lower TG by up to 77% in patients with Familial chylomicronemia syndrome (FCS) [114]”
From Targeting triglycerides for cardiovascular risk reduction (2026) · cites this paper as [114]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Several miRNAs and antisense oligonucleotides (ASOs) are currently under investigation in clinical trials for various diseases (Kanasty et al., 2013;van Rooij and Kauppinen, 2014;Gaudet et al., 2015).”
From microRNA-33 Regulates ApoE Lipidation and Amyloid-β Metabolism in the Brain (2015) · cites this paper as Gaudet et al., 2015
The cited source says what the claim attributes to it.
In the citing paper
“Several novel therapies that potently reduce triglyceride levels are currently in development.[6][7][8]”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [8]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“The agent has been approved in the European Union and the United Kingdom for the treatment of familial chylomicronemia syndrome and in Brazil for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy. 23-25”
From Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome (2024) · cites this paper as [24]
Experimental — accuracy not yet measuredIn the citing paper
“In a Phase 2 trial of volanesorsen, 300 mg given weekly to HTG patients (NCT01529424), TG levels were reduced by 80%.68”
From Clinical review on triglycerides (2020) · cites this paper as [68]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
Grundy, S. M., Becker, D. M., Clark, L. T., Cooper, R., Denke, M. A., Howard, J. L., Hunninghake, D. B., Illingworth, D. R., Luepker, R. V., McBride, P. E., et al. (2002) · Civil War Book Review · Cited by 12,198
Triglycerides and Cardiovascular Disease: A Scientific Statement From the American Heart Association
Miller, M., Stone, N. J., Ballantyne, C., Bittner, V., Criqui, M. H., Ginsberg, H. N., Goldberg, A. C., Howard, W. J., Jacobson, M. S., Kris-Etherton, P. M., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182160726 · Cited by 1,871
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Triglycerides and cardiovascular disease
Nordestgaard, B. G., & Varbo, A. (2014) · The Lancet · doi:10.1016/s0140-6736(14)61177-6 · Cited by 1,419
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Remnant Cholesterol as a Causal Risk Factor for Ischemic Heart Disease
Varbo, A., Benn, M., Tybjærg-Hansen, A., Jørgensen, A. B., Frikke-Schmidt, R., & Nordestgaard, B. G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.08.1026 · Cited by 1,115
Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease
The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071
Research works printed but not linked: 1
- Brunzell JD, 1973, Trans Assoc Am Physicians, 86, 245
Cited by
Sorted by citations
Items 501–530 of 530
Weekly Journal Scan: a novel RNA-based approach to the treatment of hypertriglyceridaemia
Galiuto, L., & Volpe, M. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae351
Rare Diseases and Antisense Oligonucleotides: A Mirage or Miracle
Vaddadi, H., & Oroszi, T. L. (2024) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2024.1212003
Sobral, M. V. S., Queiroz, I., dos Santos, J. P. P., Pirolla, R. D. C., Martins, D. C., Silva, G., da Silva, D. P., Assakawa, C., Vilela, T. A. A., Filho, M. A. G., et al. (2025) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001875
Bionanocomposites for RNAi-based delivery
Katas, H., Butt, A. M., & Ishak, K. A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-26657-7.00004-0
Von Kräutern zu Pillen, Biologics und Nukleinsäuren
Lüscher, T. F., von Eckardstein, A., Beer, J. H., Räber, L., Sudano, I., Nanchen, D., Mueller, C. E., Mach, F., & Landmesser, U. (2022) · Cardiovascular Medicine · doi:10.4414/cvm.2022.02258
Jadrníčková, P., Tichý, L., Kašpráková, M. M., Václavík, P. M. J., & Freiberger, T. (2025) · Journal of clinical lipidology · doi:10.1016/j.jacl.2025.11.016
Olkowicz, M., Czyżyńska-Cichoń, I., Szupryczyńska, N., Kostogrys, R. B., Kochan, Z., Dȩbski, J., Dadlez, M., Chłopicki, S., & Smolenski, R. T. (2021) · Figshare · doi:10.6084/m9.figshare.13531904
Goyal, S., Tanigawa, Y., Zhang, W., Chai, J.-F., Almeida, M., Sim, X., Lerner, M., Chainakul, J., Ramiu, J. G., Seraphin, C., et al. (2021) · Figshare · doi:10.6084/m9.figshare.16655697
Patel, R. S., Pasea, L., Soran, H., Downie, P., Jones, R., Hingorani, A. D., Neely, D., Denaxas, S., & Hemingway, H. (2022) · Figshare · doi:10.6084/m9.figshare.20046914
Patel, R. S., Pasea, L., Soran, H., Downie, P., Jones, R., Hingorani, A. D., Neely, D., Denaxas, S., & Hemingway, H. (2022) · Figshare · doi:10.6084/m9.figshare.20046917
Katzmann, J. L., Werner, C. M., Stojaković, T., März, W., Scharnagl, H., & Laufs, U. (2020) · Figshare · doi:10.6084/m9.figshare.12401108
Katzmann, J. L., Werner, C. M., Stojaković, T., März, W., Scharnagl, H., & Laufs, U. (2020) · Figshare · doi:10.6084/m9.figshare.12401099
Wang, L., Liu, Y., Zhang, J., Wu, J., Li, Y., Wang, L., Zhang, Y., & Hong, B. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2620602
“Hepatic APOC3, a key regulator in TG metabolism and targeted by FOXO1 [50], was significantly increased by miR-96i, although this effect did not appear to significantly impact the role of miR-96 in reducing serum triglyceride levels.”
Masood, A., Qureshi, A. U. H., Khalid, Z., Shahid, H., Malik, A. R. K., Javed, S., Mandahar, M., Amanullah, A., Siddiqui, Y., Anwar, T., et al. (2026) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2026.3543
Wulff, A. B., Varbo, A., Nordestgaard, A. G., & Nordestgaard, B. G. (2026) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2026.2639678 · Cited by 2
Apolipoprotéine C3 : élément essentiel du métabolisme lipidique et nouvelle cible thérapeutique
Akkoura, L., & Vergès, B. L. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.02.009
Ahmad, C. M., Kastle, R.-A., Patel, H., Haberman, S. R., & Youkhana, M. (2026) · Cureus · doi:10.7759/cureus.105594
“APOC3 inhibition reduced hepatic APOC3 production, thereby enhancing LPL-mediated clearance of triglyceride-rich lipoproteins [14].”
Chemello, K. (2022) · theses.fr (ABES) · doi:10.70675/6f647f12za09bz494fzae02z9be71ebf2915
Therapeutic targets for cardiovascular diseases
Kumar, B., & Saini, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-43986-5.00038-2
Olezarsen for Hypertriglyceridemia: A New Therapy Update with Systematic Review and Meta-Analysis
Khan, N., Shahid, H., Choudhry, H. H. A., Irshad, M., Shaikh, H. A., Shahid, S., Afridi, F. N., Mian, S. M., Mateen, L., Khan, H., et al. (2026) · Cardiology in Review · doi:10.1097/crd.0000000000001341
Current diabetes drugs: Lessons learned and implications for next-generation therapeutics
Liao, J., Cong, Z., Liu, K., Que, H., & Liu, F. (2026) · The Innovation Drug Discovery · doi:10.59717/j.xinn-drugdisc.2026.100008
Cai, Y. N., Li, K., Ma, H., Wu, J., & Zheng, Y. (2026) · Antioxidants · doi:10.3390/antiox15070864
“For example, therapeutic approaches that aim to selectively deplete ApoC-III-enriched HDL or restore PON1 activity may represent a move toward precision medicine in lipidology [71,72].”
Zero Coronary Artery Calcium as a Marker of Vascular Resilience in High-Risk Adults
Orimoloye, O. A., Obisesan, O. H., Osei, A. D., Oredipe, O., Carnethon, M. R., Blaha, M. J., Greenland, P., & Rasmussen‐Torvik, L. J. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103031
Treatment of severe hypertriglyceridemia: a new era dawns
Larouche, M., & Gaudet, D. (2026) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgag280
Self-citationDiagnostic criteria for pancreatitis
Kakino, Y. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44736-5.00014-0
Sharma, J., Jain, M., & Rathore, J. S. (2026) · National Journal of Pharmacology and Therapeutics · doi:10.4103/njpt.njpt_62_25
Damianaki, A., Stambolliu, E., Iliakis, P., Theofilis, P., Vakka, A., Kalliakouda, E., Patsalis, P., Konstantinidis, D., & Petras, D. I. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-026-07934-y
Coan, A. C. C., Katsuyama, E. S., Lopes, R. A., Sanchez, C. V., Prata, A. A., Fukunaga, C. K., Talavera, A., & Shapiro, M. D. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.105022
Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy
Aslesh, T., & Yokota, T. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5476-7_5
Evaluating the Knockdown Activity of MALAT1 ENA Gapmers In Vitro
Iwashita, S., Shoji, T., & Koizumi, M. (2026) · Methods in molecular biology · doi:10.1007/978-1-0716-5476-7_13
Metadata
- Authors
- Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., Crooke, R. M., Witztum, J. L., Brunzell, J. D., & Kastelein, J. J. P.
- Affiliations
- University of Washington (US)
- Ionis Pharmaceuticals (United States) (US)
- Université de Montréal (CA)
- University of California San Diego (US)
- Amsterdam UMC Location University of Amsterdam (NL)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-07-30
- Volume
- 373
- Issue
- 5
- Pages
- 438-447
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2315899065
- Semantic Scholar
- b8b4f0ae969760d3373ca1d9082abfee85fe16d9
- Cited by
- 528
- References
- 51
- Citations by year
- 2026: 23 · 2025: 28 · 2024: 27 · 2023: 32 · 2022: 51 · 2021: 46 · 2020: 63 · 2019: 61 · 2018: 68 · 2017: 58 · 2016: 58 · 2015: 13
- FWCI
- 47.75
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (acceptedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- apolipoprotein C-III, antisense oligonucleotides, hypertriglyceridemia, triglyceride lowering, fibrate therapy, dose-ranging, cardiovascular risk, pancreatitis risk, triglyceride metabolism, monotherapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Dose-Response Relationship, Drug, Double-Blind Method, Drug Therapy, Combination, Female, Humans, Cholesterol, HDL, Male, Middle Aged, Oligonucleotides, Triglycerides, Hypertriglyceridemia, Apolipoprotein C-III, Fibric Acids
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
